MX357521B - 2-(R2-TIO)-10-[3-R1-PIPERAZIN-1-IL) PROPIL]-10H-FENOTIAZINA PARA TRATAR UNA ß-AMILOIDOPATIA O UNA A-SINUCLEINOPATIA Y METODO PARA EL DIAGNOSTICO O PREDIAGNOSTICO DE LAS MISMAS. - Google Patents

2-(R2-TIO)-10-[3-R1-PIPERAZIN-1-IL) PROPIL]-10H-FENOTIAZINA PARA TRATAR UNA ß-AMILOIDOPATIA O UNA A-SINUCLEINOPATIA Y METODO PARA EL DIAGNOSTICO O PREDIAGNOSTICO DE LAS MISMAS.

Info

Publication number
MX357521B
MX357521B MX2013002612A MX2013002612A MX357521B MX 357521 B MX357521 B MX 357521B MX 2013002612 A MX2013002612 A MX 2013002612A MX 2013002612 A MX2013002612 A MX 2013002612A MX 357521 B MX357521 B MX 357521B
Authority
MX
Mexico
Prior art keywords
amyloidopathy
cerebral
prediagnosis
synucleopathy
piperazin
Prior art date
Application number
MX2013002612A
Other languages
English (en)
Other versions
MX2013002612A (es
Inventor
Jens Pahnke
Original Assignee
Immungenetics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immungenetics Ag filed Critical Immungenetics Ag
Publication of MX2013002612A publication Critical patent/MX2013002612A/es
Publication of MX357521B publication Critical patent/MX357521B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C07D279/24—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
    • C07D279/28—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom with other substituents attached to the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C07D279/24—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La invención se refiere a una 2-(R2-tio)-10-[3-(4-R1-piperazin-l-i l) propil]-10H-fenotiazina de acuerdo con la fórmula general I para el tratamiento de una ß-amiloidopatía o de una a-sinucleinopatía, con depósito de proteína cerebral y actividad reducida del transportador cerebral ABCC1 concomitantes. La invención también se refiere a un método para el diagnóstico o prediagnóstico de una 3-amiloidopatía o de una a-sinucleinopatía, con depósito de proteína cerebral y actividad reducida del transportador cerebral ABCC1 concomitantes, o para la determinación del riesgo de que un individuo sea afectado por alguna de dichas enfermedades, teniendo ya el individuo una acumulación de sustancias transportadas por el transportador cerebral ABCC1.
MX2013002612A 2010-09-07 2011-08-30 2-(R2-TIO)-10-[3-R1-PIPERAZIN-1-IL) PROPIL]-10H-FENOTIAZINA PARA TRATAR UNA ß-AMILOIDOPATIA O UNA A-SINUCLEINOPATIA Y METODO PARA EL DIAGNOSTICO O PREDIAGNOSTICO DE LAS MISMAS. MX357521B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102010044561 2010-09-07
PCT/EP2011/064893 WO2012031941A2 (de) 2010-09-07 2011-08-30 2-(R²-THIO)-10-[3-(4-R1-PIPERAZIN-1-YL)PROPYL]-10H-PHENOTHIAZINE ZUR BEHANDLUNG EINER β-AMYLOIDOPATHIE ODER ALPHA-SYNUCLEOPATHIE SOWIE VERFAHREN ZU DEREN DIAGNOSE ODER PRÄDIAGNOSE

Publications (2)

Publication Number Publication Date
MX2013002612A MX2013002612A (es) 2013-08-01
MX357521B true MX357521B (es) 2018-07-12

Family

ID=44645670

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013002612A MX357521B (es) 2010-09-07 2011-08-30 2-(R2-TIO)-10-[3-R1-PIPERAZIN-1-IL) PROPIL]-10H-FENOTIAZINA PARA TRATAR UNA ß-AMILOIDOPATIA O UNA A-SINUCLEINOPATIA Y METODO PARA EL DIAGNOSTICO O PREDIAGNOSTICO DE LAS MISMAS.

Country Status (13)

Country Link
US (3) US20130184268A1 (es)
EP (3) EP2614060B1 (es)
JP (2) JP6084924B2 (es)
CN (2) CN106243060A (es)
BR (1) BR112013005472A2 (es)
CA (2) CA2870626C (es)
DE (2) DE102010062810B4 (es)
DK (2) DK2614060T3 (es)
ES (2) ES2605705T3 (es)
MX (1) MX357521B (es)
PL (2) PL2693216T3 (es)
RU (2) RU2587154C2 (es)
WO (1) WO2012031941A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023131606A1 (en) * 2022-01-04 2023-07-13 Immungenetics Ag Specific dosage of phenothiazine compounds for use in treatment or prevention of alzheimer's dementia
WO2024083822A1 (en) * 2022-10-18 2024-04-25 Immungenetics Ag Identifying a subject suffering from alzheimer's dementia or being at risk of developing alzheimer's dementia

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH365379A (de) * 1956-04-18 1962-11-15 Sandoz Ag Verfahren zur Herstellung von neuen, in 3-Stellung mit einer einwertigen Schwefelfunktion substituierten Phenothiazinen
BE568701A (es) * 1957-06-18
US3621097A (en) * 1970-03-30 1971-11-16 Jan Marcel Didier Aron Samuel Method and compositions for treatment of mental illness
US4471116A (en) * 1982-07-28 1984-09-11 Hoffmann-La Roche Inc. Substituted (10H-phenothiazin-10-L)-propyl-1-piperazines
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
AU708682B2 (en) * 1994-08-08 1999-08-12 Albert Einstein College Of Medicine Of Yeshiva University Methods for treating and/or preventing Alzheimer's disease using phenothiazines and/or thioxanthenes
DE4430091A1 (de) * 1994-08-25 1996-02-29 Bayer Ag Verwendung von N-substituierten Phenothiazinen
ES2272911T3 (es) * 2003-04-25 2007-05-01 Neurofit Sas Uso de derivados de fenotiazina piperazina en la fabricacion de un medicamento con efectos neuroprotector y/o neurotroficos sobre cns y/o pns.
DE102005014142B4 (de) * 2005-03-23 2006-11-09 Hennig Arzneimittel Gmbh & Co. Kg Pelletförmige Retardzubereitung gegen Schwindel
WO2007062862A2 (en) * 2005-12-02 2007-06-07 Ludwig Maximilians Universität München Use of calmodulin inhibitors for the treatment of neurodegenerative disorders
HUE030621T2 (en) * 2006-07-11 2017-05-29 Wista Lab Ltd Methods for the synthesis and / or purification of diaminophenothiazinium compounds
NZ577107A (en) * 2006-11-10 2012-01-12 Cara Therapeutics Inc Synthetic peptide amide ligands of the kappa opiod receptor
GB0701970D0 (en) * 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
TW200848063A (en) * 2007-04-23 2008-12-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
EP3560496A1 (en) * 2008-04-29 2019-10-30 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
EA019571B1 (ru) * 2008-04-29 2014-04-30 Фарнекст Применение сульфизоксазола для лечения болезни альцгеймера
CA2722453C (en) * 2008-04-29 2018-03-20 Pharnext New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of angiogenesis
US9399032B2 (en) * 2009-05-14 2016-07-26 The General Hospital Corporation Methods and compositions for treating degenerative and ischemic disorders

Also Published As

Publication number Publication date
DE102010062810B4 (de) 2014-03-13
CA2870626A1 (en) 2012-03-15
PL2614060T3 (pl) 2017-05-31
EP2614060A2 (de) 2013-07-17
US20150374711A1 (en) 2015-12-31
MX2013002612A (es) 2013-08-01
EP2693216B1 (de) 2018-09-12
US9370523B2 (en) 2016-06-21
DK2614060T3 (da) 2017-01-02
DE102010062810A1 (de) 2012-03-08
CN106243060A (zh) 2016-12-21
US20130184268A1 (en) 2013-07-18
CA2870626C (en) 2018-08-14
JP6084924B2 (ja) 2017-02-22
EP3097914A3 (de) 2016-12-28
JP2017019776A (ja) 2017-01-26
ES2605705T3 (es) 2017-03-15
RU2013110018A (ru) 2014-10-20
PL2693216T3 (pl) 2019-04-30
WO2012031941A2 (de) 2012-03-15
BR112013005472A2 (pt) 2020-11-10
EP2614060B1 (de) 2016-08-31
CN103237802A (zh) 2013-08-07
RU2016118021A3 (es) 2020-02-26
WO2012031941A3 (de) 2012-09-20
CA2811454C (en) 2017-03-28
EP2693216A1 (de) 2014-02-05
RU2587154C2 (ru) 2016-06-20
US20150024418A1 (en) 2015-01-22
JP2013537881A (ja) 2013-10-07
JP6426663B2 (ja) 2018-11-21
ES2701453T3 (es) 2019-02-22
CN103237802B (zh) 2017-06-09
EP3097914A2 (de) 2016-11-30
DK2693216T3 (en) 2019-01-14
RU2016118021A (ru) 2018-11-01
DE102011053114A1 (de) 2012-03-08
CA2811454A1 (en) 2012-03-15

Similar Documents

Publication Publication Date Title
CY1120246T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
CY1121981T1 (el) Μεθοδος για τον προσδιορισμο κινδυνου pml
ATE458732T1 (de) Verwendung von 4-imidazol-derivaten für zns- erkrankungen
SMT201400072B (it) Nuovi composti utili per il trattamento di malattie degenerative e infiammatorie
EA201170872A1 (ru) Ингибиторы протеинкиназы
EA201300583A1 (ru) Вазопротективное и кардиопротективное противодиабетическое лечение
CR20170001A (es) Anticuerpos anti factor d humanizados
MA34091B1 (fr) Anticorps anti-cd40
WO2011112687A3 (en) Heterocyclic inhibitors of histamine receptors for the treatment of disease
MX2010007406A (es) Anticuerpos anti-factor inhibidor de migracion de macrofago (mif).
IT1401447B1 (it) Metodo per il trasferimento quantitativo di analiti
DK2368118T3 (da) Biomarkører til inhibitorer med anti-angiogen aktivitet
HK1153538A1 (en) Pro-endothelin-1 levels for the prediction of risk of tachyarrhytmic events -1
ZA201005384B (en) Substituted arylamide diazepinopyrimidone derivatives for the treatment of neurodegenerative diseases caused by abnormal activity of gsk3-beta
SMT201700090B (it) Donatori di nitrossile per il trattamento di ipertensione polmonare
DE602006010449D1 (de) Behandlung von geflügel zwecks reduzierung der futon ascites
NL2003068A1 (nl) Parallel process focus compensation.
WO2012097052A3 (en) Monosaccharide-based compounds for the treatment of proliferative and inflammatory dermatological diseases
FR2980271B1 (fr) Procede de determination de la glycosylation d'un anticorps
AU2012313353A8 (en) Screening method
MX357521B (es) 2-(R2-TIO)-10-[3-R1-PIPERAZIN-1-IL) PROPIL]-10H-FENOTIAZINA PARA TRATAR UNA ß-AMILOIDOPATIA O UNA A-SINUCLEINOPATIA Y METODO PARA EL DIAGNOSTICO O PREDIAGNOSTICO DE LAS MISMAS.
MX2012012092A (es) Sintesis novedosa para compuestos de tiazolidinadiona.
WO2010020647A3 (en) New method for identifying compounds useful for treating and/or preventing disease-associated with bone loss
FR2979549B1 (fr) Systeme et methode de traitement des reflux zootechniques civils et industriels et des boues et purins.
MX342289B (es) Sintesis para compuestos de tiazolidindiona.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: IMMUNGENETICS AG

FG Grant or registration